[Edaily Reporter KIM SAE-MI ] “Through a study on patient-derived tissue recently presented at the Society for Immunotherapy of Cancer (SITC) in the U.S., we have confirmed the potential for our next-generation immuno-oncology drug ‘AR170’ to stand out from the competition. Once we secure key data—including the results of additional translational research and non-human primate toxicity studies (GLP-Tox)—in the first half of next year, discussions with global pharmaceutical companies regarding an early technology transfer will gain even more momentum.”
Park Beom-chan, co-CEO of Y-Biologics, Inc., met with E-Daily in Yeouido, Seoul, on the 16th to explain the significance of the research findings presented at the Society for Immunotherapy of Cancer (SITC) conference. (Photo: ReporterKIM SAE-MI ) Park Beom-chan, Co-CEO of Y-Biologics ( Y-Biologics, Inc(338840) ), met with E-Daily in Yeouido, Seoul, on the 16th to explain the significance of the research findings recently presented at SITC 2026. The company plans to verify the potential of its new drug candidate to activate immune cells using actual cancer patient tissue and, based on this, pursue technology export at the preclinical stage next year.
T-Cell Proliferation in Patient Tissue Compared to Competitor Drugs… “The Data Big Pharma Wants”
The key asset CEO Park is highlighting in technology export negotiations is translational research using actual cancer patient tissue. The data recently presented at SITC 2026 also focused on this aspect.
“Since the immune systems of mice and humans differ, a drug may not work in humans even if it shows excellent results in animals,” he explained. “To bridge that gap, we applied the drug directly to cancer patient tissue.”
Translational research data from samples of patients with intractable solid tumors (Source: Y-Biologics, Inc.)
The study observed the proliferation patterns of tumor-specific T cells and CD8 T cells that attack cancer cells. According to the company, AR170 demonstrated potential for expanded indications in tissue derived from colorectal cancer patients, while AR166 showed potential for expanded indications across multiple cancer types, including liver, kidney, lung, and colorectal cancers. Initial responses were also observed in ovarian cancer. Notably, AR166 exhibited a CD8 T-cell proliferation effect approximately twice as high as that of the comparator drug “IBI363” in tissue derived from renal cell carcinoma patients.
CEO Park stated, “Compared to ‘Keytruda,’ ‘Ibonecimab,’ and IBI363, our drug increased T-cells by several times,” adding, “This is exactly the kind of patient tissue data that global pharmaceutical companies want to see.”
He emphasized that outstanding anticancer efficacy was also confirmed in animal studies. “In a mouse colorectal cancer model, AR170’s tumor-suppressing effect was more than three times higher than that of ibonesimab, and complete remission was observed in about half of the cases,” he explained, adding, “After 55 days of observation, 80% of the AR170-treated group survived, whereas no survivors were found in the ibonesimab-treated group.”
However, since fewer than 10 patient-derived tissue samples were secured for each cancer type, it is difficult to definitively confirm consistent efficacy or superiority over competing drugs based solely on these results. Accordingly, the company plans to sequentially achieve key milestones in the first half of next year, including increasing the number of patient-derived tissue samples to 40–50 by the time the American Association for Cancer Research (AACR) conference is held next year and publishing the research results in a scientific paper.
CEO Park stated, “Even if we secure only about 50% of the translational research data, we will achieve statistical significance and be able to substantially complete a preclinical data package that global pharmaceutical companies can trust.” He added, “Based on this, we plan to publish a paper in a leading academic journal with a high impact factor and supplement this with GLP-Tox (nonclinical toxicity testing) data from non-human primates.”
Interest in technology transfer from global companies is also on the rise. He hinted, “Recently, two MNCs (multinational corporations) have expressed more active interest than before,” adding, “While it is still difficult to disclose specific details regarding contract negotiations, this data has helped increase interest from global partners.”
AR170: Early Technology Export; AR166: Value Enhancement… A Two-Track Strategy
Y-Biologics, Inc is prioritizing the early technology export of AR170 while pursuing a strategy to enhance the value of AR166 by securing additional data.
CEO Park commented, “When I attended this year’s AACR conference, I noticed that about three Chinese companies presented approaches similar to ours,” adding, “Since both PD-1/VEGF bispecific antibodies and PD-1/IL-2 conjugation technologies have emerged as core pillars of next-generation immuno-oncology therapies, a global consensus has formed regarding the direction of integrating these two technologies.”
AR170 is a candidate drug that combines a PD-1×VEGF bispecific antibody with an interleukin-2 variant (IL-2v) that induces the proliferation of immune cells. The company aims to secure a technology export deal for AR170 at the preclinical stage and submit an Investigational New Drug (IND) application next year.
CEO Park anticipates that competition with Chinese companies will intensify once clinical trials begin. He noted, “We assess that these Chinese companies are slightly behind us in terms of development,” but added, “Once clinical trials actually begin, China is extremely fast at recruiting patients, so we determined that a strategy of partnering with a global pharmaceutical company before entering clinical trials to maximize development speed would be effective for AR170.”
The company has also adopted a flexible approach to technology licensing. CEO Park emphasized, “Whether a global pharmaceutical company conducts clinical trials directly in China or the U.S., or we handle development domestically under a contract where they cover clinical trial costs, AR170 must move quickly,” adding, “Only then will we avoid losing opportunities in the competitive landscape.”
On the other hand, the company believes there is room to increase the value of “AR166,” another key new drug candidate, over a relatively longer period of time. AR166 is a triple-antibody that combines a PD-1×LAG-3 bispecific antibody with IL-2v. CEO Park expressed confidence, stating, “To date, we have not found any competing compounds with the same structure as AR166,” and added, “It has the potential to be a first-in-class drug.”
AR170: Targeting an IND Application in the Second Half of Next Year… CMC Also Progressing Smoothly
GLP toxicity testing of AR170 in monkeys is scheduled to begin at the end of next month. CEO Park expects to submit an Investigational New Drug (IND) application in the U.S. by the second half of next year, with the domestic application potentially preceding that. The initial clinical trial will determine the optimal dosage in patients with various solid tumors, while the efficacy of AR170 will be evaluated primarily in lung cancer patients. The company is also considering expanding the indications to include colorectal cancer and other conditions in the future.
Process development for mass production is also proceeding smoothly. CEO Park stated, “Despite the structural complexity of a triple-target antibody-cytokine fusion protein, productivity is higher than expected, so the drug manufacturing and quality control (CMC) process is proceeding steadily according to schedule.” He added, “Since we have secured favorable results even in the initial 15-liter pilot production, I do not foresee any major issues in completing the production of clinical trial samples by June of next year.”
Genexine, Inc.(095700)is securing the cash needed for research and development and operations by disposing of its financial assets, but its debt and interest burden remain significant.
Genexine, In…
NamyangDairyProducts(003920)’s protein brand “TakeFit” saw its cumulative sales for the third quarter of this year increase by 48.3% compared to the same period last year. Analysts attribute this grow…
“Through a study on patient-derived tissue recently presented at the Society for Immunotherapy of Cancer (SITC) in the U.S., we have confirmed the potential for our next-generation immuno-oncology dru…